Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
|Articles|June 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 6
- Volume 16
- Issue 6
FDA Approves Torisel for Renal Cell Carcinoma
FDA has approved Wyeth's Torisel (temsirolimus) for the treatment of advanced renal cell carcinoma, based on a study showing prolonged survival with Torisel as a single agent vs interferon alfa
Advertisement
ROCKVILLE, MarylandFDA has approved Wyeth's Torisel (temsirolimus) for the treatment of advanced renal cell carcinoma, based on a study showing prolonged survival with Torisel as a single agent vs interferon alfa. Median overall survival was 10.9 months for Torisel patients vs 7.3 months for interferon patients. Progression-free survival increased from 3.1 months with interferon to 5.5 months with Torisel. The combination of Torisel and interferon did not result in a significant increase in overall survival, compared with interferon alone. Look for a complete report on the approval in the July issue of ONI.
Articles in this issue
over 19 years ago
ACS Launches Major Epidemiology Studyover 19 years ago
Pt Selection Key to Radioembolization of Liver Ca'sover 19 years ago
Million Dollar Gotham Prize Announcedover 19 years ago
Diagnostic Dilemma: GI Diseaseover 19 years ago
Junovan Fails to Win ODAC Nod for Osteosarcoma Treatmentover 19 years ago
Surveillance Colonoscopy Guidelines Not Being Followedover 19 years ago
Removing Stage IV Primary May Cut Mortalityover 19 years ago
Nuclear Export Inhibitors Testing Moving Forwardover 19 years ago
ODAC: orBec Yields No 'Substantial Efficacy' in GI GVHDAdvertisement
Related to this article
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5